In some patients, we could also exclusively detect mutations in melanoma driver genes (BRAF, NRAS, MAP2K1, KIT) suggesting that CTC analysis could complement ctDNA analysis for relevant clinical implications in personalized medicine in oncology. The gene discussed is MAP2K1; the disease is melanoma.